
Diversifying Clinical Trial Participation: Pathways from screenings to trials
Includes a Live Web Event on 06/04/2025 at 1:00 PM (EDT)
-
Register
- General Attendee - Free!
- Speaker - Free!
- Prevent Cancer Foundation Staff - Free!
In this session learners will hear about how to move clinical trials closer to the prevention space—and how to connect earlier with patients and communities with information about and access to clinical trials. Our presenters will speak about successful programs that address the importance of building public trust and ways to make early enrollment and adherence feasible for more people. Learn about who is deemed "eligible” for trials and how that impacts certain cohorts of patients. How can the greater cancer care community address these gaps—what interventions have been utilized and proven helpful?
Learning Objectives:
1. Identify interventions to address patient hesitancy and increase trust in trials
2. Identify approaches to enhance early trial enrollment within the cancer care continuum
3. Identify grassroots approaches to making drug trials more inclusive
4. Identify interventions to discover barriers to enrollment
5. Explore new care models that address clinical trial engagement before diagnostic confirmation and/or cancer diagnosis

Dina G. Lansey, MSN, RN
The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dina Lansey is an Assistant Professor of Oncology in the Johns Hopkins School of Medicine and serves as the Assistant Director for Clinical Research and Population Sciences at the Sidney Kimmel Comprehensive Cancer Center.
Dina has led SKCCC efforts to improve the inclusion of women, minorities, and other underrepresented patient groups in clinical trials since 2012. Her efforts to understanding barriers to trial participation as they appear in practice and to develop interventions to address them through research, policy changes, education, patient supportive care services and community outreach and engagement have led to significant declines in long standing trial participation disparities at the Center. Today, her work also includes identifying and addressing the socioeconomic, environmental and structural barriers that influence disparities in cancer risk reduction, screening and access to treatment.
Dina received her B.S.N from the Johns Hopkins School of Nursing and M.S.N from Drexel University. She is currently a doctoral candidate at the Johns Hopkins Bloomberg School of Public Health. Her dissertation is focused on environmental justice and its influence on cancer health disparities.

Kenan Onel, MD, PhD
Roswell Park Comprehensive Cancer Center
Kenan Onel, MD, PhD, is a Professor of Oncology at the Roswell Park Comprehensive Cancer Center, where he leads the new Department of Clinical Genomics and is founding Director of the Center for Precision Oncology and Cancer Prevention. Dr Onel is a physician/scientist who studies the genetic contribution to cancer risk and response to therapy. As a physician, he is Board-certified in Pediatric Oncology and has spent his career as a clinical cancer geneticist caring for families at high risk for cancer due to their genetics or family history. As a scientist, he is known internationally for his work on the genetic contribution to cancer risk and response to therapy and is recognized as a leader in functional genomics, an emerging field integrating genetic and laboratory investigations that is yielding profound new insights into human health and disease. He has a long history of NIH and foundation funding, and has published almost 100 articles, reviews, and book chapters.

Luis G. Carvajal-Carmona, PhD
University of California, Davis
Dr. Luis Carvajal-Carmona is the Associate Vice Chancellor for Academic Diversity and a Professor of Biochemistry and Molecular Medicine at the University of California at Davis (UCD). He holds the Auburn Community Cancer Endowed Chair in Basic Science. He serves as the Center for Advancing Cancer Health Director and co-director of the Community Engagement Program at the Clinical and Translational Science Center. Dr. Carvajal-Carmona obtained his Ph.D. from University College London, completed postdoctoral training at the London Research Institute, and was a Senior Research Fellow at the University of Oxford. Dr. Carvajal-Carmona specializes in cancer genetics, epidemiology, health disparities, and global health. He has discovered multiple cancer genes and has published over 100 research manuscripts. His main contributions to science include the elucidation of the genetic origins of Latino populations, discovering the first common variants increasing the risk of colorectal cancer, and identifying a novel familial form of gastric cancer.
Key:





Certified Health Education Specialist (CHES):
Sponsored by the Prevent Cancer Foundation (provider number 125052), a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc., this program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 1.75 total Category I Continuing Education Contact Hours (CECH). Maximum advanced-level Continuing Education Contact Hours available are 0. Continuing Competency credits available are 0. Content will be provided in the following areas of responsibility for health education specialists: Area V: Advocacy.
Nursing:
This activity has been evaluated and approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women's Health for 1.75 CE continuing education contact hours. NPWH Activity number 25-09-02. CA CEP Number 13411.